NCT01731002

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 224 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost

Conditions

• Ocular Hypertension
• Open Angle Glaucoma

Interventions

Type	Name	Description
DRUG	AR-13324 Ophthalmic Solution 0.01%	Administered to study eye, once daily (QD) in the evening (PM) for 28 days
DRUG	AR-13324 Ophthalmic Solution 0.02%	Administered to study eye, QD in the PM for 28 days
DRUG	Latanoprost ophthalmic solution 0.005%	Administered to study eye, QD in the PM for 28 days

Timeline

• Start date: 2012-11-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2012-11-21
• Last updated: 2018-04-17
• Results posted: 2018-04-17

Locations

22 sites across 1 country: United States